SCHEMBL17544697

SCHEMBL17544697

CC(=O)N1CCCc2cccc(O)c21

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.59
P2RX1 P51575 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 3/20 0.46
RAB9A P51151 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
TSHR P16473 1/20 0.46
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
ALOX12 P18054 1/20 0.42
HSD17B3 P37058 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14591324 0.84 NOTUM (0.59) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL29216428 0.83 NOTUM (0.58) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3720316 0.83 NOTUM (0.58) NOTUMSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL19603153 0.81 NOTUM (0.56) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL11537014 0.80 P2RX1 (0.50) NOTUMP2RX1SMN1; SMN2ALDH1A1RAB9A
SCHEMBL3145336 0.80 ALDH1A1 (0.51) P2RX1SMN1; SMN2ALDH1A1RAB9AHPGD
SCHEMBL6108617 0.80 P2RX1 (0.50) NOTUMP2RX1SMN1; SMN2ALDH1A1RAB9A
SCHEMBL19447114 0.79 NOTUM (0.55) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL19603446 0.78 NOTUM (0.52) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL29216430 0.78 NOTUM (0.52) NOTUMSMN1; SMN2ALDH1A1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4070795-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME Salk Institute for Biological Studies (US) 2022-10-12 EP disclosed
EP-3185868-B1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INST FOR BIOLOGICAL STUDI (US) 2022-04-06 EP disclosed
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 US disclosed
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 US disclosed
US-10689397-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-06-23 US disclosed
US-10689397-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-06-23 US disclosed
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-09-19 US disclosed
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-09-19 US disclosed
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-08-15 US disclosed
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-08-15 US disclosed
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-05-23 US disclosed
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-05-23 US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
EP-3185868-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME Salk Institute for Biological Studies (US) 2017-07-05 EP disclosed
WO-2016033100-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-03-03 WO disclosed
WO-2016033100-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689397-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 NOTUM 3044/4885P2RX1 1883/4885SMN1; SMN2 1143/4885
US-10266549-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 NOTUM 3044/4885P2RX1 1883/4885SMN1; SMN2 1143/4885
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 NOTUM 3070/4885P2RX1 1518/4885SMN1; SMN2 1309/4885
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 NOTUM 3070/4885P2RX1 1518/4885SMN1; SMN2 1309/4885
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 NOTUM 3070/4885P2RX1 1518/4885SMN1; SMN2 1309/4885
US-10774092-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 NOTUM 3044/4885P2RX1 1883/4885SMN1; SMN2 1143/4885
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 NOTUM 3070/4885P2RX1 1518/4885SMN1; SMN2 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.